Clinical Trials and Research

XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of 35 mg twice daily Xanamem™ in Subjects with mild dementia due to Alzheimer’s Disease (AD).

MISSION AD1: Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease.

AWARE: A Phase 2 Multiple Dose, Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer’s Disease.

A multicenter, randomized, double-blinded, active control, phase III clinical trial for evaluation of Donepezil patch in Alzheimer’s disease patients.

DEFERIPRONE To Delay Dementia (The 3D Study): A Clinical Proof Of Concept Study.

GRADUATE: A Phase III Multicentre Randomised Double-blinded Placebo Controlled Parallel Group Efficacy and Safety Study of Gantanrumab in Patients with Prodromal to Mild AD.

A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION OF PHASE III STUDIES. (BN29552/BN29553) OF CRENEZUMAB IN PATIENTS WITH ALZHEIMER’S DISEASE.

A 5-Year, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of Two Amyloid Lowering Agents, CAD106 and a BACE 1 Inhibitor, on Postponing Cognitive Decline in Cognitively Unimpaired APOE4 Homozygotes Elderly Subjects at Risk for the Onset of Clinical Symptoms due to Alzheimer Disease.

OPEN LABEL EXTENSION STUDY FOR CONTINUED SAFETY AND EFFICACY EVALUATION OF AZELIRAGON IN PATIENTS WITH MILD ALZHEIMER’S DISEASE.